• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Checkpoint Therapeutics Inc.

    6/9/25 8:05:40 AM ET
    $CKPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CKPT alert in real time by email
    15-12G 1 tm2516501d1_15-12g.htm 15-12G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER
    SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION
    OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number  001-38128

     

    CHECKPOINT THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    2 Independence Way

    Princeton, New Jersey 08540
    (781) 652-4500
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Common Stock, par value $0.0001 per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

      Rule 12g-4(a)(1) x  
      Rule 12g-4(a)(2) ¨  
      Rule 12h-3(b)(1)(i) x  
      Rule 12h-3(b)(1)(ii) ¨  
      Rule 15d-6 ¨  
      Rule 15d-22(b) ¨  

     

    Approximate number of holders of record as of the certification or notice date: one (1).

     

     

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Checkpoint Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

    Date: June 9, 2025 CHECKPOINT THERAPEUTICS, INC.
       
      By: /s/ Erik Zwicker
      Name: Erik Zwicker
      Title: Secretary

     

     

     

     

    Get the next $CKPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CKPT

    DatePrice TargetRatingAnalyst
    1/13/2025$9.00Buy
    D. Boral Capital
    7/14/2022$7.00Buy
    B. Riley Securities
    1/25/2022$17.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CKPT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Checkpoint Therapeutics Inc.

      15-12G - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

      6/9/25 8:05:40 AM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Checkpoint Therapeutics Inc.

      EFFECT - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

      6/5/25 12:15:07 AM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Checkpoint Therapeutics Inc.

      EFFECT - Checkpoint Therapeutics, Inc. (0001651407) (Filer)

      6/5/25 12:15:08 AM ET
      $CKPT
      Biotechnology: Pharmaceutical Preparations
      Health Care